June 6, 2024

Comprehensive Audiologic Analyses After Cisplatin-Based Chemotherapy

Puntos clave

Los puntos clave no están disponibles para este artículo en este momento.

Resumen

Cisplatin is highly ototoxic but widely used. Evidence is lacking regarding cisplatin-related hearing loss (CRHL) in adult-onset cancer survivors with comprehensive audiologic assessments (eg, Words-in-Noise WIN tests, full-spectrum audiometry, and additional otologic measures), as well as the progression of CRHL considering comorbidities, modifiable factors associated with risk, and cumulative cisplatin dose.

Me gusta

Guardar

Cite This Study

Sanchez et al. (Thu,) studied this question.

synapsesocial.com/papers/68e65d00b6db6435875eb0d8 https://doi.org/https://doi.org/10.1001/jamaoncol.2024.1233

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Uses and abuses of hearing loss classification.1981 · 866 citations
2Untitled2022 · 6 citations
3Speech perception 30 years after cisplatin-based chemotherapy in adults: limited clinical relevance of long-term ototoxicity?2021 · 7 citations
4Comprehensive Audiometric Analysis of Hearing Impairment and Tinnitus After Cisplatin-Based Chemotherapy in Survivors of Adult-Onset Cancer2016 · 281 citations
5Speech-in-Noise Tests and Supra-threshold Auditory Evoked Potentials as Metrics for Noise Damage and Clinical Trial Outcome Measures2016 · 42 citations

Me gusta

Guardar